Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Investors" LOL! - J
Sure there has definitely been some conversions, but all news has been rather vanilla with a passive approach and minimal follow-up. I would think investors would be interested in timelines, next steps/milestones, NIH path and success implications, OSA program updates, funding status/efforts etc, etc.
Although maybe the "short-term loosen purse strings" comment is alluding to their current focus and efforts....
I disagree, Jeff has been increasing the float to the best of his abilities.
Considering all the positive traction with their drug candidates, they are not doing a very good job of what you suggest.... if that is the intent...
Well,
IMO, RSPI can be much more potent and lucrative. Advancing through robust NIH preclinicals and all the positive studies completed with epilepsy and pain.... just feels like this is a really big pharma deal, not simply OTC type of deal...
I'm sure that Jeff is comitted to adressing the float issue.
Right on DTGoody. RSPI gonna be great
I am still here, and I will not go Anywhere!!! This will be the next RGBP in my opinion. That ran from .002 to .08 cents in three days with 3.5 Billion shares in the Float.
Just like RGBP ran after it got its Big Pharma Partnership, so will RSPI run when we get our Big Pharma Partnership Announcement.
Unlike RGBP with it's tradable float of 3.5 Billion with a 5 Billion OS, our RSPI entire AS is only @ 2 Billion shares.
RSPI is the easiest buy and hold for me:
Outstanding Shares
774,682,161
04/02/2024
Held at DTC or (Tradable Float)
728,897,301
04/02/2024
Averaging down is critical with RSPI. You must always average down - J
RSPI going to be huge sharky
good time to average down. the only thing that could ruin this is the infamous Reverse Split, which fortunately, has not been mentioned as of yet. LONG AND STRONG, adding at these levels could possibly yield a great ROI glta
Spot on Sharky!
No approved drug available yet for this. The alternative treatments presently are uncomfortable, and I believe I had read a few weeks back could have links to cancer.
We are in the proverbial sweet spot for several breakthroughs imho.
Patience!
Dronabinol, a synthetic version of ?-9-THC, a naturally occurring substance in the cannabis plant, has already demonstrated significant improvement in the symptoms of OSA in two phase 2 clinical trials. OSA impacts an estimated 29.4 million people in the United States and has been linked to increased risk for hypertension, heart failure, depression, and diabetes. There are no approved drug treatments for OSA.
$RSPI
Yeah, it would only be logical that a drug candidate that has progressed extremely positively in the NIH preclinicals would already have engagement with big pharma. Purpose of the new hire 4 months ago? Assumption is they are in tier 3 preclinicals now with NIH, no timeline given to complete, but CEO mentioned loosinenig "pursestrings" in the short term. Really it could happen any day, I suppose. One would think all parties including NIH would want to see success rolled immediately into or ASAP into human clinical trials.
I can only assume the OSA program is underway with preclinical trials as well, but no update there for quite some time.
This is the OTC, so speculative money only, but personally I love the risk v. reward potential here. GLTA.
Have a good friend…
Battling to get off opioids. It’s been a struggle with migraines as a result. Trying to do it right. If Pharma’s have potential solution these folks need to get off their multi billion dollar pocket books and get some real solutions out there!!!
It’s coming imho. Huge high exposure will begin to drive this up and hopefully get things rolling for the folks needing help!!
Glad to be a part of the solution!!
Notice of Late Filing
https://www.otcmarkets.com/filing/html?id=17417768&guid=J1Q-karWJBwfJth
Many of these sub penny stocks are filing late.
The good thing is they are filing!
Good morning all, our eggs will hatch in time.
$RSPI
Agree in a sense that the company really hasnt provided any input recently as to milestones/targets, expectations, etc. Couple that with the convertible debt that needs to be mitigated, then I suppose it explains the fledgling stock. The only thing mentioned in recent press is hoping to find financing to advance the SCI/ADHD program later this year.
That leaves the OSA program, which has some funding set up in Australia and presumably conducting some pre-clinicals on new formulations?
And the pain/epilepsy candidate in NIH tier 3 trials, presumably underway but no idea when to expect results?
And CEO hoping to open "pursestrings" now with very positive preclinical data in hand.
Feels like very significant irons in the fire that when/if pulled out will be white hot. Just no idea on timing. Hoping 10-K will shed some insight.
GLTA.
There is something more than meets the eye with this stock.
With the current pipeline and OS. This should be much much higher...
Something isn't right...
No reason for this to be at these levels, but we know nothing about the workings of this company.
Somone with much more information is keeping this down at these levels.
My opinion
There is something more than meets the eye with this stock.
With the current pipeline and OS. This should be much much higher...
Something isn't right...
No reason for this to be at these levels, but we know nothing about the workings of this company.
Somone with much more information is keeping this down at these levels.
My opinion
Buy more please, I'm depending on it. -J
If you are looking for "probable", then that money needs to seek mutual funds and bonds.
The "possible" is where speculative funds play and it is how OTC stocks generate those 50x, 100x, 200x type returns...
IMO, what we are looking for are signs that the IP is increasing in value and progressing to the next step. Moving from "possible" to "probable" and generating massive ROI.
Agree completely. The market cap is ridiculous here and there are plenty of OTC stocks trading 5-10 million valuation with no IP, no significant assets; let alone an extremely promising drug candidate that has progressed to final preclinical stages within the NIH program to mitigate the opioid crisis! amongst other promising drug candidates!
Couple that with new VP and institutional debt getting shares at .0015 and some preclinical acquisitions and deals in the pharma business netting 100s of millions, this truly becomes a no brainer!
Good luck, my average is just over .0009 so now just holding unless it drops in the .0005 range but I hope and don't see it happening.
I guess i have some catching up to do
Thanks I have ten million even , I am good
Jack you are on the wrong board.
The runs is the jaguar health board.
I got 9.89 million shares i would like to sell for 10 cents per share if you want them
Undervalued MC 774,682 👍
No brainer. We could easily be waiting at 10 million versus sub 1 million for updates.
The move can happen at anytime imho!
I also continue to accumulate.
Easily with partnership/funding to further their pain/epilepsy drug candidate post-NIH final preclinical trials. That would only be a 40 mil market cap now. Even if OS doubles, 80 mil market cap would seem very cheap considering the implications of success in mitigating opioid crisis as well as the size of that market…
There is just not clear visibility of timing of “possible” success there, nor timeline status of other programs like OSA. Could be 6 days or 6 months or longer? I am content accumulating.
It is possible.. but not probable
why was this at 0007 few weeks ago
It would be nice to see .05+ in the next few months
Hard to put a timeline/price on any speculative investment. Note the wording investment and not trade.
My perspective is there are two possibily extremely valuable and lucrative paths they are on in the near term. OSA drug program and Epilepsy/Pain drug program.
The OSA program has some funding set-up and pieces in place it appears. Their approach is logical and hopefully the new technology can overcome past hinderances. It makes sense that it very well could and will, however needs proven. Maybe they are waiting on further patent news, or FDA or additional funding or ??? or maybe we will hear something soon too.
The Epilepsy/Pain progress is substantial, IMO. Google search the candidate, review the reports and listen to the interviews. Something more than a peanut farm is brewing with this. Odds of success are always low in drug development, but their current positive progress certainly has increased their chances significantly. Success on this path, IMO, will make this one of the most valuable OTC pharma historically. How long to wrap up the NIH final trials? Months, Quarters? How much dilution is left? Are there big pharmas now, "purse strings" in the mix?
Success is surely not guaranteed. Timing is unknown. But I am in the camp you do just accumulate for the long haul. Whether days or months or quarters down the road. Steps taken and noted in the filings appear to be positioning for success, although such is never guaranteed. GLTA.
Ok. I will pick up a few at .0006 this time
This was and will always be 3+ by end of 2014. Guranteed!
As a newbie, do any of you experienced investors think it likely this stock sp will reach a penny by end of 2014?
True. However...
There is evidence in the filings of increasing confidence hence the fixed price salary for new exec and debt settlement and good terms eliminating some debt, 0% with .0015 fixed price for both. Minimal expectations of trading many multiples of that higher to make those decisions wise, IMO. Also the moves towards payable events, etc. Curious if the 10-K due soon will highlight additional clean-up in this regard.
Couple that with all the volume being absorbed... roughly 500 million shares maybe since right before bringing in their dealmaker? Why the sudden increase for previously/past boring turtle level progress?
Clearly recognize the risk, as with all OTC's especially, but hard not to be excited about the potential considering confirmed progress. Good as any place for speculative dollars, IMO.
The history looms heavy. Much investment was sunk in the past, and it made the ticker radioactive. But there was a reason why this happened, the promise and the science is extremely compelling. It still is, since the company has been “artificially” kept alive a long, long time. I’d make an analogy to the AI winter. AI was a radioactive term for a long, long time too.
A simple fact is always you need to see: they keep diluting the crap out of this and it won't stop. Why is that? Don't see the great potential here? Why is no one buying this out? Come on man... we are not all Trumpers to believe that theory
Agree. Anyone can look at the success probability of any drug development and see that the average is extremely low. Always massive risk vs massive reward in pharma space, especially OTC.
It is valuable to hear input from a historical perspective, so any tidbits to consider positive or negative should always be welcome. From a cursory look, it appears they have been working on addressing these unmet pharma needs for a decade. Lack of funding and failure is expected and looks to be experienced historically.
IMO, I see two very plausible and positive paths they are currently on.
In regards to OSA, I think newer technology related to nanotech and controlled release is logically more likely to help overcome the past trials where it appears the path was correct, but ability to get to finish line more than uncertain to unlock the investment risk. It appears the new approach makes more sense and is much more possible for success. Couple it with some improved financing options in place, I think they are on to something. I think everyone would be curious as to a status update of that program.
In regards to Epilepsy/Pain candidate drug. All the DD, whether interviews, independent publications or commentary appears extremely enthusiastic and optimistic. Clearing the NIH hurdles in presumably robust preclinicals is more than promising. Considering the opioid crisis and national headlines, and the current progress in the NIH program, one can imagine the possibilities here far exceed historical comparable OTC pharmas.
IMO, the speculative value is much much higher than current reflections in the market so I will accumulate over time.
Jeff would like people keep buying. This is more important than setting and forgetting it. He will let you know when we are near the set/forget phase.
Followers
|
327
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
47033
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators oldstocks DTGoody powerbattles fly_fisherman archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
8-K | 10/02/2023 | 09/26/2023 | PDFRTFHTMLXLS |
10-Q | 08/21/2023 | 06/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 08/14/2023 | 06/30/2023 | PDFRTFHTML |
8-K | 08/09/2023 | 08/03/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |